SEngine Precision Medicine

SEngine Precision Medicine has developed an innovative approach to identify and develop the next generation of targeted cancer drugs. With its founders having over 25 years of experience at the Fred Hutchinson Cancer Research Center, SEngine utilizes functional genomics and drug robotic testing in live patient-derived organoids to match newly developed drugs with individual cancer patients. SEngine is committed to fulfilling the promise of personalized medicine by providing cancer patients with effective, targeted, and low-toxicity treatments.